Other 1. AUG 2023
Does a mandatory switch from originator adalimumab to biosimilar GP2017 or SB5 lead to increased hospital costs? A DANBIO study of >1,300 patients with inflammatory arthritis
Authors:
- N. Nabi
- Rikke Ibsen
- M. Ibsen
- Jakob Kjellberg
- M. Hetland
- B. Glintborg
Authors
About this publication
Published in
Scandinavian journal of rheumatology
